MDxHealth/Sumitomo Sign Molecular Diagnostic Partnership
MDxHealth has signed a partnership agreement with Summit Pharmaceuticals International, a subsidiary of Sumitomo Corporation, to gain access to the Japanese market with its pharmaco molecular diagnostic (PharmacoMDx) epigenetic technologies and products. Expanding upon MDxHealth's PharmacoMDx programme, the partnership aims to provide companion diagnostic solutions, or theranostics, to pharmaceutical companies in the Japanese market. No financial terms have been disclosed. MDxHealth's PharmacoMDx team leverages next-generation and deep sequencing technologies for the identification and validation of powerful epigenetic biomarkers for novel therapeutics.